Insmed (INSM) EBITDA (2010 - 2026)

Insmed's EBITDA history runs 17 years deep, the most recent figure standing at -$153.3 million for Q1 2026.

• On a quarterly basis, EBITDA rose 38.21% year-over-year to -$153.3 million in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 17.44% decrease from a year earlier, with the FY2025 full-year figure at -$1.2 billion, down 41.96% from the prior year.
• EBITDA rose to -$153.3 million in Q1 2026 per INSM's latest filing, from -$319.7 million in the prior quarter.
• Across five years, EBITDA topped out at -$88.3 million in Q2 2022 and bottomed at -$366.0 million in Q3 2025.
• The 5-year median for EBITDA is -$178.3 million (2023), against an average of -$202.7 million.
• Across the five-year window, EBITDA slumped 166.69% in 2023 and surged 38.21% in 2026, its largest moves.
• Year by year, EBITDA stood at -$151.5 million in 2022, then slipped by 17.69% to -$178.3 million in 2023, then slipped by 29.25% to -$230.4 million in 2024, then slumped by 38.77% to -$319.7 million in 2025, then surged by 52.05% to -$153.3 million in 2026.
• Per Business Quant, the three latest INSM EBITDA figures stand at -$153.3 million (Q1 2026), -$319.7 million (Q4 2025), and -$366.0 million (Q3 2025).